BriaCell Therapeutics’ Bria-IMT gets FDA fast track status in breast cancer
BriaCell Therapeutics has secured the fast track status from the US Food and Drug Administration (FDA) for its lead candidate — Bria-IMT for the treatment of metastatic breast cancer. The US-based clinical-stage biotech company specializes in targeted immunotherapies for cancer. Bria-IMT is a cell-based immunotherapy, which has been designed to preferentially kill tumor cells without […]